Skip to main content
Top
Published in: Malaria Journal 1/2012

Open Access 01-12-2012 | Research

The magnitude and trend of artemether-lumefantrine stock-outs at public health facilities in Kenya

Authors: Raymond K Sudoi, Sophie Githinji, Andrew Nyandigisi, Alex Muturi, Robert W Snow, Dejan Zurovac

Published in: Malaria Journal | Issue 1/2012

Login to get access

Abstract

Background

Health facility stock-outs of artemether-lumefantrine (AL), the common first-line therapy for uncomplicated malaria across Africa, adversely affect effective malaria case-management. They have been previously reported on various scales in time and space, however the magnitude of the problem and trends over time are less clear. Here, 2010-2011 data are reported from public facilities in Kenya where alarming stock-outs were revealed in 2008.

Methods

Data were collected between January 2010 and June 2011 as part of 18 monthly cross-sectional surveys undertaken at nationally representative samples of public health facilities. The primary monitoring indicator was total stock-out of all four weight-specific AL packs. The secondary indicators were stock-outs of at least one AL pack and individual stock-outs for each AL pack. Monthly proportions and summary means of the proportions over the monitoring period were measured for each indicator. Stock-out trends were assessed using linear regression.

Results

The number of surveyed facilities across 18 time points ranged between 162 and 176 facilities. The stock-out means of the proportion of health facilities were 11.6% for total AL stock-out, 40.6% for stock-out of at least one AL pack, and between 20.5% and 27.4% for stock-outs of individual AL packs. Monthly decrease of the total AL stock-out was 0.005% (95% CI: -0.5 to +0.5; p = 0.983). Monthly decrease in the stock-out of at least one AL pack was 0.7% (95% CI: -1.5 to +0.3; p = 0.058) while stock-outs of individual AL packs decreased monthly between 0.2% for AL 24-pack and 0.7% for AL six-pack without statistical significance for any of the weight-specific packs.

Conclusions

Despite lower levels of AL stock-outs compared to the reports in 2008, the stock-outs at Kenyan facilities during 2010-2011 are still substantial and of particular worry for the most detrimental:- simultaneous absence of any AL pack. Only minor decrease was observed in the stock-outs of individual AL packs. Recently launched interventions to eliminate AL stock-outs in Kenya are fully justified.
Appendix
Available only for authorised users
Literature
1.
go back to reference Whitty CJM, Chandler C, Ansah E, Leslie T, Staedke S: Deployment of ACT antimalarials for treatment of malaria: challenges and opportunities. Malar J. 2008, 7 (Suppl 1): S7-10.1186/1475-2875-7-S1-S7.PubMedCentralCrossRefPubMed Whitty CJM, Chandler C, Ansah E, Leslie T, Staedke S: Deployment of ACT antimalarials for treatment of malaria: challenges and opportunities. Malar J. 2008, 7 (Suppl 1): S7-10.1186/1475-2875-7-S1-S7.PubMedCentralCrossRefPubMed
2.
go back to reference O'Connell KA, Gatakaa H, Poyer S, Njogu J, Evance I, Munroe E, Solomon T, Goodman C, Hanson K, Zinsou C, Akulayi L, Raharinjatovo J, Arogundade E, Buyungo P, Mpasela F, Adjibabi CB, Agbango JA, Ramarosandratana BF, Coker B, Rubahika D, Hamainza B, Chapman S, Shewchuk T, Chavasse D: Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries. Malar J. 2011, 10: 328-10.1186/1475-2875-10-328.PubMedCentralCrossRefPubMed O'Connell KA, Gatakaa H, Poyer S, Njogu J, Evance I, Munroe E, Solomon T, Goodman C, Hanson K, Zinsou C, Akulayi L, Raharinjatovo J, Arogundade E, Buyungo P, Mpasela F, Adjibabi CB, Agbango JA, Ramarosandratana BF, Coker B, Rubahika D, Hamainza B, Chapman S, Shewchuk T, Chavasse D: Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries. Malar J. 2011, 10: 328-10.1186/1475-2875-10-328.PubMedCentralCrossRefPubMed
3.
go back to reference Diap G, Amuasi J, Boakye I, Sevcsik AM, Pecoul B: Anti-malarial market and policy surveys in sub-Saharan Africa. Malar J. 2010, 9 (Suppl 1): S1-10.1186/1475-2875-9-S1-S1.CrossRefPubMed Diap G, Amuasi J, Boakye I, Sevcsik AM, Pecoul B: Anti-malarial market and policy surveys in sub-Saharan Africa. Malar J. 2010, 9 (Suppl 1): S1-10.1186/1475-2875-9-S1-S1.CrossRefPubMed
4.
go back to reference Zurovac D, Ndhlovu M, Sipilanyambe N, Chanda P, Hamer DH, Simon JL, Snow RW: Paediatric malaria case-management with artemether-lumefantrine in Zambia: a repeat cross-sectional study. Malar J. 2007, 6: 31-10.1186/1475-2875-6-31.PubMedCentralCrossRefPubMed Zurovac D, Ndhlovu M, Sipilanyambe N, Chanda P, Hamer DH, Simon JL, Snow RW: Paediatric malaria case-management with artemether-lumefantrine in Zambia: a repeat cross-sectional study. Malar J. 2007, 6: 31-10.1186/1475-2875-6-31.PubMedCentralCrossRefPubMed
5.
go back to reference Zurovac D, Tibenderana JK, Nankabirwa J, Ssekitooleko J, Njogu JN, Rwakimari JB, Meek S, Talisuna A, Snow RW: Malaria case-management under artemether-lumefantrine treatment policy in Uganda. Malar J. 2008, 7: 181-10.1186/1475-2875-7-181.PubMedCentralCrossRefPubMed Zurovac D, Tibenderana JK, Nankabirwa J, Ssekitooleko J, Njogu JN, Rwakimari JB, Meek S, Talisuna A, Snow RW: Malaria case-management under artemether-lumefantrine treatment policy in Uganda. Malar J. 2008, 7: 181-10.1186/1475-2875-7-181.PubMedCentralCrossRefPubMed
6.
go back to reference Time for a ''Third Wave'' of malaria activism to tackle the drug stock-out crisis. Plos Med. Edited by: The PLoS Medicine. 2009, 6: e1000188. Time for a ''Third Wave'' of malaria activism to tackle the drug stock-out crisis. Plos Med. Edited by: The PLoS Medicine. 2009, 6: e1000188.
7.
go back to reference Amin AA, Zurovac D, Kangwana BB, Greenfield J, Otieno DN, Akhwale WS, Snow RW: The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya. Malar J. 2007, 6: 72-10.1186/1475-2875-6-72.PubMedCentralCrossRefPubMed Amin AA, Zurovac D, Kangwana BB, Greenfield J, Otieno DN, Akhwale WS, Snow RW: The challenges of changing national malaria drug policy to artemisinin-based combinations in Kenya. Malar J. 2007, 6: 72-10.1186/1475-2875-6-72.PubMedCentralCrossRefPubMed
8.
go back to reference Kangwana BB, Njogu J, Kedenge SV, Memusi DN, Goodman CA, Zurovac D, Snow RW: Malaria drug shortages in Kenya - a major failure to provide access to effective treatment. Am J Trop Med Hyg. 2009, 80: 737-738.PubMedCentralPubMed Kangwana BB, Njogu J, Kedenge SV, Memusi DN, Goodman CA, Zurovac D, Snow RW: Malaria drug shortages in Kenya - a major failure to provide access to effective treatment. Am J Trop Med Hyg. 2009, 80: 737-738.PubMedCentralPubMed
9.
go back to reference Ministry of Public Health and Sanitation: Kenya Malaria Monitoring and Evaluation Plan 2009-2017. 2009, Division of Malaria Control, Nairobi Ministry of Public Health and Sanitation: Kenya Malaria Monitoring and Evaluation Plan 2009-2017. 2009, Division of Malaria Control, Nairobi
10.
go back to reference Juma E, Zurovac D: Changes in health workers' malaria diagnosis and treatment practices in Kenya. Malar J. 2010, 10: 1.CrossRef Juma E, Zurovac D: Changes in health workers' malaria diagnosis and treatment practices in Kenya. Malar J. 2010, 10: 1.CrossRef
11.
go back to reference Nyandigisi A, Memusi D, Mbithi A, Ang'wa N, Shieshia M, Muturi A, Sudoi RK, Githinji S, Juma A, Zurovac D: Malaria case-management following change of policy to universal parasitological diagnosis and targeted artemisinin-based combination therapy in Kenya. PLoS One. 2011, 6: e24781-10.1371/journal.pone.0024781.PubMedCentralCrossRefPubMed Nyandigisi A, Memusi D, Mbithi A, Ang'wa N, Shieshia M, Muturi A, Sudoi RK, Githinji S, Juma A, Zurovac D: Malaria case-management following change of policy to universal parasitological diagnosis and targeted artemisinin-based combination therapy in Kenya. PLoS One. 2011, 6: e24781-10.1371/journal.pone.0024781.PubMedCentralCrossRefPubMed
12.
13.
go back to reference Hamel M, Adazu K, Obuor D, Sewe M, Vulule J, Williamson JM, Slutsker L, Feikin DR, Laserson KF: Reversal in reductions in child mortality in Western Kenya, 2003-2009. Am J Trop Med Hyg. 2011, 85: 597-605. 10.4269/ajtmh.2011.10-0678.PubMedCentralCrossRefPubMed Hamel M, Adazu K, Obuor D, Sewe M, Vulule J, Williamson JM, Slutsker L, Feikin DR, Laserson KF: Reversal in reductions in child mortality in Western Kenya, 2003-2009. Am J Trop Med Hyg. 2011, 85: 597-605. 10.4269/ajtmh.2011.10-0678.PubMedCentralCrossRefPubMed
14.
go back to reference Fogg C, Bajunirwe F, Piola P, Biraro S, Grandesso F, Ruzagira E, Babigumira J, Kigozi I, Kiguli J, Kyomuhendo J, Ferradini L, Taylor W, Checchi F, Guthmann JP: Adherence to a six-dose regimen of artemether-Lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Uganda. Am J Trop Med Hyg. 2004, 5: 525-535. Fogg C, Bajunirwe F, Piola P, Biraro S, Grandesso F, Ruzagira E, Babigumira J, Kigozi I, Kiguli J, Kyomuhendo J, Ferradini L, Taylor W, Checchi F, Guthmann JP: Adherence to a six-dose regimen of artemether-Lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Uganda. Am J Trop Med Hyg. 2004, 5: 525-535.
15.
go back to reference Bell DJ, Wootton D, Mukaka M, Montgomery J, Kayange N, Chimpeni P, Hughes DA, Molyneux ME, Ward SA, Winstanley PA, Lalloo DG: Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi. Malar J. 2009, 8: 204-10.1186/1475-2875-8-204.PubMedCentralCrossRefPubMed Bell DJ, Wootton D, Mukaka M, Montgomery J, Kayange N, Chimpeni P, Hughes DA, Molyneux ME, Ward SA, Winstanley PA, Lalloo DG: Measurement of adherence, drug concentrations and the effectiveness of artemether-lumefantrine, chlorproguanil-dapsone or sulphadoxine-pyrimethamine in the treatment of uncomplicated malaria in Malawi. Malar J. 2009, 8: 204-10.1186/1475-2875-8-204.PubMedCentralCrossRefPubMed
16.
go back to reference Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, Ruzagira E, Babigumira J, Kigozi I, Kiguli J, Kyomuhendo J, Ferradini L, Taylor W, Checchi F, Guthmann JP: Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. Lancet. 2005, 365: 1467-1473. 10.1016/S0140-6736(05)66416-1.CrossRefPubMed Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, Ruzagira E, Babigumira J, Kigozi I, Kiguli J, Kyomuhendo J, Ferradini L, Taylor W, Checchi F, Guthmann JP: Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. Lancet. 2005, 365: 1467-1473. 10.1016/S0140-6736(05)66416-1.CrossRefPubMed
17.
go back to reference Beer N, Ali AS, Rotllant G, Abass AK, Omari RS, Al-mafazy AH: Adherence to artesunate-amodiaquine combination therapy for uncomplicated malaria in children in Zanzibar, Tanzania. Trop Med Int Health. 2009, 14: 1-9.CrossRef Beer N, Ali AS, Rotllant G, Abass AK, Omari RS, Al-mafazy AH: Adherence to artesunate-amodiaquine combination therapy for uncomplicated malaria in children in Zanzibar, Tanzania. Trop Med Int Health. 2009, 14: 1-9.CrossRef
18.
go back to reference Gerstl S, Dunkley S, Mukhtar A, Baker S, Maikere J: Successful introduction of artesunate combination therapy is not enough to fight malaria: results from an adherence study in Sierra Leone. Trans R Soc Trop Med Hyg. 2010, 104: 328-335. 10.1016/j.trstmh.2009.12.008.CrossRefPubMed Gerstl S, Dunkley S, Mukhtar A, Baker S, Maikere J: Successful introduction of artesunate combination therapy is not enough to fight malaria: results from an adherence study in Sierra Leone. Trans R Soc Trop Med Hyg. 2010, 104: 328-335. 10.1016/j.trstmh.2009.12.008.CrossRefPubMed
19.
go back to reference Lawford H, Zurovac D, O'Reilly L, Hoibak S, Cowley A, Munga S, Vulule J, Juma E, Snow RW, Allan R: Adherence to prescribed artemisinin-based combination therapy in Garissa and Bunyala districts, Kenya. Malar J. 2011, 10: 281-10.1186/1475-2875-10-281.PubMedCentralCrossRefPubMed Lawford H, Zurovac D, O'Reilly L, Hoibak S, Cowley A, Munga S, Vulule J, Juma E, Snow RW, Allan R: Adherence to prescribed artemisinin-based combination therapy in Garissa and Bunyala districts, Kenya. Malar J. 2011, 10: 281-10.1186/1475-2875-10-281.PubMedCentralCrossRefPubMed
20.
go back to reference Mace KE, Mwandama D, Jafali J, Luka M, Filler SJ, Sande J, Ali D, Kachur SP, Mathanga DP, Skarbinski J: Adherence to treatment with artemether-lumefantrine for uncomplicated malaria in rural Malawi. Clin Infect Dis. 2011, 53: 772-779. 10.1093/cid/cir498.CrossRefPubMed Mace KE, Mwandama D, Jafali J, Luka M, Filler SJ, Sande J, Ali D, Kachur SP, Mathanga DP, Skarbinski J: Adherence to treatment with artemether-lumefantrine for uncomplicated malaria in rural Malawi. Clin Infect Dis. 2011, 53: 772-779. 10.1093/cid/cir498.CrossRefPubMed
21.
go back to reference Barrington J, Wereko-Brobby O, Ward P, Mwafongo W, Kungulwe S: SMS for Life: a pilot project to improve anti-malarial drug supply management in rural Tanzania using standard technology. Malar J. 2010, 9: 298-10.1186/1475-2875-9-298.PubMedCentralCrossRefPubMed Barrington J, Wereko-Brobby O, Ward P, Mwafongo W, Kungulwe S: SMS for Life: a pilot project to improve anti-malarial drug supply management in rural Tanzania using standard technology. Malar J. 2010, 9: 298-10.1186/1475-2875-9-298.PubMedCentralCrossRefPubMed
Metadata
Title
The magnitude and trend of artemether-lumefantrine stock-outs at public health facilities in Kenya
Authors
Raymond K Sudoi
Sophie Githinji
Andrew Nyandigisi
Alex Muturi
Robert W Snow
Dejan Zurovac
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2012
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/1475-2875-11-37

Other articles of this Issue 1/2012

Malaria Journal 1/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.